JP2019505485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505485A5 JP2019505485A5 JP2018530075A JP2018530075A JP2019505485A5 JP 2019505485 A5 JP2019505485 A5 JP 2019505485A5 JP 2018530075 A JP2018530075 A JP 2018530075A JP 2018530075 A JP2018530075 A JP 2018530075A JP 2019505485 A5 JP2019505485 A5 JP 2019505485A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- egfr
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022081697A JP7494245B2 (ja) | 2015-12-11 | 2022-05-18 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266470P | 2015-12-11 | 2015-12-11 | |
| US62/266,470 | 2015-12-11 | ||
| US201662380177P | 2016-08-26 | 2016-08-26 | |
| US62/380,177 | 2016-08-26 | ||
| PCT/US2016/065641 WO2017100462A2 (en) | 2015-12-11 | 2016-12-08 | Treatment of cancer with dual targeting of cd47 and egfr |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022081697A Division JP7494245B2 (ja) | 2015-12-11 | 2022-05-18 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505485A JP2019505485A (ja) | 2019-02-28 |
| JP2019505485A5 true JP2019505485A5 (https=) | 2019-12-05 |
| JP7077226B2 JP7077226B2 (ja) | 2022-05-30 |
Family
ID=59013321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530075A Active JP7077226B2 (ja) | 2015-12-11 | 2016-12-08 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
| JP2022081697A Active JP7494245B2 (ja) | 2015-12-11 | 2022-05-18 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022081697A Active JP7494245B2 (ja) | 2015-12-11 | 2022-05-18 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10344094B2 (https=) |
| EP (1) | EP3386545A4 (https=) |
| JP (2) | JP7077226B2 (https=) |
| KR (2) | KR20250004896A (https=) |
| CN (2) | CN115569192A (https=) |
| AU (3) | AU2016365829B2 (https=) |
| CA (1) | CA3005911A1 (https=) |
| WO (1) | WO2017100462A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10568383B2 (en) * | 2015-01-16 | 2020-02-25 | Nike, Inc. | Sole system for an article of footwear incorporating a knitted component with a one-piece knit outsole and a tensile element |
| US9848673B2 (en) | 2015-01-16 | 2017-12-26 | Nike, Inc. | Vacuum formed knit sole system for an article of footwear incorporating a knitted component |
| EP3341015B2 (en) * | 2015-08-26 | 2023-12-27 | The Board of Trustees of the Leland Stanford Junior University | Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist |
| AU2016365829B2 (en) * | 2015-12-11 | 2020-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of CD47 and EGFR |
| EP3747906A1 (en) | 2016-01-11 | 2020-12-09 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| EP3532497B1 (en) | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| SI4177270T1 (sl) * | 2017-10-18 | 2024-10-30 | Forty Seven, Inc. | Terapija za raka jajčnikov na osnovi sredstva proti cd47 |
| KR20200091901A (ko) | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
| AU2019218271B2 (en) | 2018-02-12 | 2024-12-12 | Forty Seven, LLC | Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies |
| US20210040219A1 (en) * | 2018-03-13 | 2021-02-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by egfr antibody |
| MX2020009774A (es) | 2018-03-21 | 2020-10-08 | Alx Oncology Inc | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. |
| CN110331200A (zh) * | 2019-06-28 | 2019-10-15 | 中山大学附属第六医院 | Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用 |
| WO2021046216A1 (en) * | 2019-09-03 | 2021-03-11 | Arch Oncology, Inc. | Methods for identifying biomarkers to predict treatment response |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| WO2023165618A1 (en) * | 2022-03-04 | 2023-09-07 | Nanjing University | Methods for treating cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| PL2560658T3 (pl) * | 2010-04-21 | 2017-08-31 | Ventirx Pharmaceuticals, Inc. | Wzmacnianie cytotoksyczności komórkowej zależnej od przeciwciał |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| CN105399831A (zh) | 2010-10-29 | 2016-03-16 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
| US9233171B2 (en) * | 2011-11-21 | 2016-01-12 | Immunogen, Inc. | Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate |
| SI2804617T1 (sl) | 2012-01-17 | 2020-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Visokoafinitetni SIRP-alfa reagenti |
| US20140134158A1 (en) * | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| CN105121467B (zh) * | 2012-12-03 | 2019-07-05 | 诺夫免疫股份有限公司 | 抗cd47抗体及其使用方法 |
| CN105101997B (zh) * | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | 不减少血小板和不减少血红细胞的cd47抗体及其使用方法 |
| AU2014227638A1 (en) * | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| PT2970493T (pt) | 2013-03-15 | 2019-06-27 | Univ Leland Stanford Junior | Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47 |
| ES2898627T3 (es) | 2013-04-29 | 2022-03-08 | Univ Leland Stanford Junior | Uso de agentes anti-CD47 para mejorar la inmunización |
| ES3012974T3 (en) * | 2014-01-08 | 2025-04-10 | Univ Leland Stanford Junior | Targeted therapy for lung cancer |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| EP3209769B1 (en) * | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| US20160036232A1 (en) | 2015-10-09 | 2016-02-04 | LT Lighting (Taiwan) Corp. | Maximum energy utilization point tracking technologies |
| AU2016365829B2 (en) * | 2015-12-11 | 2020-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of CD47 and EGFR |
| CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
| CN106519036B (zh) * | 2016-11-04 | 2019-06-11 | 新乡医学院 | 抗cd47和egfr的双功能蛋白及其制备方法与应用 |
-
2016
- 2016-12-08 AU AU2016365829A patent/AU2016365829B2/en active Active
- 2016-12-08 KR KR1020247039741A patent/KR20250004896A/ko active Pending
- 2016-12-08 KR KR1020187016533A patent/KR102763202B1/ko active Active
- 2016-12-08 CN CN202210862489.8A patent/CN115569192A/zh active Pending
- 2016-12-08 CA CA3005911A patent/CA3005911A1/en active Pending
- 2016-12-08 EP EP16873852.4A patent/EP3386545A4/en active Pending
- 2016-12-08 WO PCT/US2016/065641 patent/WO2017100462A2/en not_active Ceased
- 2016-12-08 US US15/373,150 patent/US10344094B2/en active Active
- 2016-12-08 CN CN201680072080.9A patent/CN108367073A/zh active Pending
- 2016-12-08 JP JP2018530075A patent/JP7077226B2/ja active Active
-
2019
- 2019-05-14 US US16/411,547 patent/US11130813B2/en active Active
-
2020
- 2020-04-23 AU AU2020202712A patent/AU2020202712B2/en active Active
-
2021
- 2021-08-25 US US17/411,953 patent/US12037402B2/en active Active
-
2022
- 2022-05-18 JP JP2022081697A patent/JP7494245B2/ja active Active
-
2023
- 2023-03-30 AU AU2023201938A patent/AU2023201938B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505485A5 (https=) | ||
| JOP20220225B1 (ar) | ميوتينات إنترليوكين-21 وطرق العلاج | |
| Biton et al. | TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti–PD-1 in lung adenocarcinoma | |
| Dosset et al. | PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer | |
| Heinecke et al. | Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression | |
| Sektioglu et al. | Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection | |
| Patel et al. | Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition | |
| JP2015500002A5 (https=) | ||
| SA520411173B1 (ar) | Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137 | |
| UA108912C2 (uk) | БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| ATE419277T1 (de) | Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen | |
| WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| Chi et al. | Classification of non-small cell lung cancer’s tumor immune micro-environment and strategies to augment its response to immune checkpoint blockade | |
| MA35208B1 (fr) | Protéines de liaison à bcma (cd269/tnfrsf17) | |
| RU2014133069A (ru) | Транслокации r-спондина и способы с их использованием | |
| IL187321A (en) | Host cell specific binding molecules encoding monoclonal antibodies capable of neutralizing viruses, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments | |
| EA201890941A1 (ru) | Программируемые универсальные клеточные рецепторы и способы их применения | |
| Chen et al. | Dissecting the tumor–immune landscape in chimeric antigen receptor T-cell therapy: key challenges and opportunities for a systems immunology approach | |
| CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
| JP2015510882A5 (https=) | ||
| MX2025010337A (es) | Anticuerpos contra el factor c2b del complemento humano y metodos de uso | |
| Mordzińska-Rak et al. | Advancing head and neck cancer therapies: from conventional treatments to emerging strategies | |
| EA201491352A1 (ru) | Способ лечения рака груди |